InflaRx

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell InflaRx and other ETFs, options, and stocks.

About IFRX

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. 

CEO
Niels Christoph Riedemann
CEONiels Christoph Riedemann
Employees
65
Employees65
Headquarters
Jena, Thueringen
HeadquartersJena, Thueringen
Founded
2007
Founded2007
Employees
65
Employees65

IFRX Key Statistics

Market cap
181.46M
Market cap181.46M
Price-Earnings ratio
-1.88
Price-Earnings ratio-1.88
Dividend yield
Dividend yield
Average volume
3.37M
Average volume3.37M
High today
$2.86
High today$2.86
Low today
$1.85
Low today$1.85
Open price
$2.55
Open price$2.55
Volume
18.26M
Volume18.26M
52 Week high
$2.86
52 Week high$2.86
52 Week low
$0.7113
52 Week low$0.7113

Stock Snapshot

The current InflaRx(IFRX) stock price is $2.58, with a market capitalization of 181.46M. The stock trades at a price-to-earnings (P/E) ratio of -1.88.

On 2026-05-06, InflaRx(IFRX) stock traded between a low of $1.85 and a high of $2.86. Shares are currently priced at $2.58, which is +39.4% above the low and -9.8% below the high.

The InflaRx(IFRX)'s current trading volume is 18.26M, compared to an average daily volume of 3.37M.

During the past year, InflaRx(IFRX) stock moved between $0.71 at its lowest and $2.86 at its peak.

During the past year, InflaRx(IFRX) stock moved between $0.71 at its lowest and $2.86 at its peak.

IFRX News

TipRanks 11h
InflaRx Refocuses Izicopan on Vasculitis and Renal Diseases With Funding Runway to 2029

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 2d
InflaRx Highlights Favorable Safety-Signal Data for Izicopan in New Preclinical Study

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 3d
InflaRx announces new izicopan pre-clinical data

InflaRx (IFRX) announced new pre-clinical data demonstrating low reactive metabolite formation of izicopan in human liver microsomes. Reactive metabolite format...

Analyst ratings

75%

of 8 ratings
Buy
75%
Hold
25%
Sell
0%

People also own

Based on the portfolios of people who own IFRX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.